If you are a hem/onc pharmacist and have ever felt de-valued by the metrics that capture your work you’ve got to fill out this survey!!! Thanks in advance for responding and helping make a difference to improve onc workforce retention! https://t.co/TiD79c46bj
Check out our #HERO consortium poster 4267 TODAY at #ASH23! We compared ATRA+ATO+GO vs ATRA+ATO+Ida in HR APL
🩸In real world, 69% of the GO arm required ida for cytoreduction (so not truly chemo free)
🩸🟰 efficacy
🩸🟰 composite safety, but ⬇️ duration of neutropenia in GO arm
Listen to "All too well: the reality of leukemia treatment"! In an extra special episode, @ajperissinotti@Berninini and @Lydialbc discuss the ALL treatment journey with a former patient, Madeline! A must-listen for anyone who takes care of AYA patients! https://t.co/XSYQW4ONd9
Seeing some problematic leukemia takes lately…
We should NOT be abandoning phase III trials or changing practice based on single-institution/arm data. There are countless examples of approaches that look promising in phase II / single-center studies that can’t be replicated!
Listen to "Episode 13: You get blinatumomab! You get blinatumomab!" where we talk about Oprah's favorite drug! Here, @Lydialbc and the Twitterless Patrick Burke help us decide whether the ECOG1910 trial is practice changing! Should MRD- patients get blin? https://t.co/969CFnmoet
@KyleGrose9@Berninini@WolverHeme@FirasElChaer The fact we do not know this answer is the reason we try our best NOT to switch. There are no good clinical data to say outcomes will be preserved if we switch to Erwinia/Rylaze. The observational data have significant confounders. We do graded challenge with PEG and TDM.
This makes me so annoyed. How can you claim to be concerned about equity and access, then claim an event that will cost a student $1k+ is a “can’t miss”! Programs and candidates need to align and evolve. No way 900 programs should be traveling cross country for this. Do better.
@justinhreid I hear you and you are not alone. It’s really unfortunate that we always feel like the only things we can cut out are the things we enjoy the most. At some point the career we trained so hard for becomes unrecognizable
Phenomenal @atoppsummit talk on the #GreatMigration of Oncology Pharmacists out of clinical practice by @AlisonGulbis, @kamakshi_rao, @kczmj! Over ❗️2/3❗️considering a career change. Our work environments seem to be as toxic ☢️ as the chemo we give. How can we fix this???